Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers

Launched by M.D. ANDERSON CANCER CENTER · Sep 16, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to detect cancer cells in women with high-risk endometrial cancer, which includes specific types like clear cell and serous adenocarcinoma. Instead of a traditional tissue biopsy, which involves taking a sample of tissue, this study uses a liquid biopsy—a simple blood test. Researchers want to see if this blood test can effectively find cancer cells and help doctors understand how these cells change during treatment.

To be eligible for this trial, participants must be women aged 18 and older who have been diagnosed with high-risk uterine cancer and are planning to undergo surgery. It’s important to note that women who have already received treatment for their endometrial cancer, such as surgery or chemotherapy, cannot participate. If you join the study, you will provide blood and tissue samples, which will be used to help researchers learn more about the disease and potentially improve future detection and treatment methods.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women age 18 years and older
• • Histologic diagnosis of endometrial cancer
• • Candidate for primary surgical treatment or has recently had prior primary surgery
• • Willing and able to provide informed consent
• Exclusion Criteria:
• • Patients who have received prior treatment including chemotherapy or radiation therapy for endometrial cancer. Patients with prior primary surgery will be allowed to enroll in this trial if the patient has not received any chemotherapy or radiation at the time of enrollment. Note: patients with a history of other cancers may be enrolled after discussion with the PI if it is determined that they are at low risk for recurrence or metastasis.